Lipoprotein
Familial Hyperlipidemias
Laboratory Measurement
Cholesterol and Atherogenesis
Lipid and Lipoprotein Basics
Clinical Lipid Management
Successful early studies reported for two Lp(a)-lowering therapies
The first oral treatment to lower lipoprotein(a) safely lowered Lp(a) in a phase 1 study, whereas an extended phase 2 study showed durable Lp(a) lowering by an injectable treatment, researchers reported.
VIDEO: Lp(a) testing often warranted, but how to treat high levels unclear
ARLINGTON, Texas — In this Healio video exclusive, an expert breaks down a session on the significance of lipoprotein(a) at the American Society for Preventive Cardiology Congress on CVD Prevention.
VIDEO: The latest in lipid-lowering therapy at NLA with Christie M. Ballantyne
In this Healio | Cardiology Today video exclusive, Christie M. Ballantyne, MD, FACC, FACP, FAHA, FNLA, provided a review of the NLA Scientific Session opening session, “The Latest in Lipid Lowering Therapy – It's Not Just a Phase.”
Lp(a) level varies widely among Hispanic US adults
Median lipoprotein(a) levels vary widely among Hispanic or Latino U.S. adults, with the highest median values seen among those self-identifying as Cuban, Dominican or Puerto Rican, researchers reported.
Lipoprotein(a): The next frontier in CV risk reduction
This installment of Pipeline Pulse focuses on a single cardiovascular risk factor, lipoprotein(a), and examines two CV outcomes trials aimed at reducing CV events through Lp(a) reduction.